Insider Transactions in Q3 2025 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,294
-1.81%
|
$109,410
$15.84 P/Share
|
|
Sep 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+3.74%
|
-
|
|
Aug 25
2025
|
Nicole Sweeny Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,480
-4.38%
|
$19,240
$13.42 P/Share
|
|
Aug 25
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,336
-1.87%
|
$30,368
$13.42 P/Share
|
|
Aug 25
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,954
-1.46%
|
$25,402
$13.42 P/Share
|
|
Aug 22
2025
|
Nicole Sweeny Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.9%
|
-
|
|
Aug 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.85%
|
-
|
|
Aug 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+2.28%
|
-
|
|
Aug 22
2025
|
Nicole Sweeny Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,864
-6.08%
|
$24,232
$13.22 P/Share
|
|
Aug 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,942
-2.4%
|
$38,246
$13.22 P/Share
|
|
Aug 22
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,940
-2.75%
|
$142,220
$13.22 P/Share
|
|
Aug 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,362
-1.77%
|
$30,706
$13.22 P/Share
|
|
Aug 21
2025
|
Nicole Sweeny Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+16.94%
|
-
|
|
Aug 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.84%
|
-
|
|
Aug 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+5.52%
|
-
|
|
Aug 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+2.74%
|
-
|
|
Aug 18
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,409
-1.16%
|
$57,317
$13.19 P/Share
|
|
Aug 18
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,939
-2.46%
|
$38,207
$13.19 P/Share
|
|
Aug 18
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,649
-2.0%
|
$34,437
$13.19 P/Share
|
|
Aug 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,362
+2.41%
|
-
|
|
Aug 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,446
+5.12%
|
-
|
|
Aug 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,203
+3.08%
|
-
|
|
Jul 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
32,979
-8.19%
|
$494,685
$15.69 P/Share
|
|
Jul 09
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
30,250
-19.12%
|
$453,750
$15.69 P/Share
|
|
Jul 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+17.85%
|
-
|
|
Jul 08
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.5%
|
-
|